| Therapeutic interventions to enhance apolipoprotein A-I-mediated cardioprotection. | |
| | |
MedLine Citation:
|
PMID: 20297868 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The principal function of high-density lipoprotein (HDL) is to facilitate the reverse cholesterol transport (RCT) and inhibition of atheroma formation. Epidemiological studies and interventional trials have suggested that HDL has cardioprotective properties. However, increasing HDL concentration may not necessarily increase RCT, especially if the increase in HDL levels is the result of inhibiting HDL cholesterol (HDL-C) flux. The results of recent phase III clinical trials utilizing a cholesterol ester transfer protein (CETP) inhibitor to increase HDL-C levels in hypoalphalipoproteinaemia have shown that this approach of elevating HDL-C levels is insufficient to combat atherosclerosis and reduce the risk of cardiovascular disease. Although there are several interventions that increase HDL-C by preventing its turnover in the circulation, a more desirable approach is to enhance de novo production of HDL in the liver and/or small intestine. To this end, our acquired knowledge of the apolipoprotein-I (apo A-I) gene promoter as well as the signalling pathways that modulate its expression, has fuelled the development of novel therapeutic strategies to increase HDL-C flux. Promising pharmacological agents that selectively regulate transcription of the apo A-I gene, therapeutic strategies to de-repress apo A-I gene expression, and infusion of recombinant apo A-I or apo A-I mimetics are under development and may be clinically beneficial in the near future. |
| | |
Authors:
|
Michael J Haas; Arshag D Mooradian |
Related Documents
:
|
7130858 - Isolation of human serum hdl1 by zonal ultracentrifugation. 20631298 - Effects of weight loss, induced by gastric bypass surgery, on hdl remodeling in obese w... 15930518 - Heterogeneity of high density lipoprotein generated by abca1 and abca7. 15841208 - Targeted inactivation of hepatic abca1 causes profound hypoalphalipoproteinemia and kid... 9607128 - Lowering of serum cholesteryl ester transfer protein--but not lecithin:cholesterol acyl... 16726258 - Effects of feeding endophyte-infected tall fescue seed on the reproductive performance ... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't; Review |
Journal Detail:
|
Title: Drugs Volume: 70 ISSN: 0012-6667 ISO Abbreviation: Drugs Publication Date: 2010 May |
Date Detail:
|
Created Date: 2010-04-29 Completed Date: 2010-07-16 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7600076 Medline TA: Drugs Country: New Zealand |
Other Details:
|
Languages: eng Pagination: 805-21 Citation Subset: IM |
Affiliation:
|
Department of Medicine, University of Florida College of Medicine, Jacksonville, Florida 32209, USA. michael.haas@jax.ufl.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Apolipoprotein A-I / biosynthesis*, genetics Biological Transport Cardiotonic Agents / pharmacology, therapeutic use* Cardiovascular Diseases / drug therapy*, metabolism Cholesterol / metabolism* Drug Design* Humans Lipoproteins, HDL / biosynthesis* Promoter Regions, Genetic / drug effects Receptors, Cytoplasmic and Nuclear / agonists, antagonists & inhibitors Transcription, Genetic / drug effects |
| Chemical | |
Reg. No./Substance:
|
0/Apolipoprotein A-I; 0/Cardiotonic Agents; 0/Lipoproteins, HDL; 0/Receptors, Cytoplasmic and Nuclear; 57-88-5/Cholesterol |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: B Cell-Targeted Therapies for Systemic Lupus Erythematosus: An Update on Clinical Trial Data.
Next Document: Evaluation of a rural chronic disease self-management program.